Abstract: PO0289
Patient Preferences Study for Treatments of Anemia in CKD Patients Not on Dialysis (NDD)
Session Information
- Anemia and Iron Management
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Alexandre, Ana filipa, Astellas Pharma Europe B.V., Leiden, Netherlands
- Morga, Antonia, Astellas Pharma Europe Ltd, Addlestone, United Kingdom
- Thomas, Caitlin, Evidera, London, United Kingdom
- Krucien, Nicolas, Evidera, London, United Kingdom
- Tervonen, Tommi, Evidera, London, United Kingdom
- Jiletcovici, Alina, Astellas Pharma, Inc., Northbrook, Illinois, United States
- Marsh, Kevin Patrick, Evidera, London, United Kingdom
Background
Erythropoietin analogues (EAs) are a mainstay of treatment of anemia in adult patients with CKD but they are associated with increased risk of cardiovascular (CV) events. Furthermore, their mode of administration (intravenous or subcutaneous [SC]) may represent a barrier to some patients. As such, the aim of this study was to understand patients’ valuation of attributes associated with CKD anemia treatments.
Methods
Adult (≥18 years) patients from UK, Spain, Germany, and France, who had self-reported NDD CKD anemia and were being treated with EAs, participated in this online discrete choice experiment (DCE). Patients were presented with choice tasks, each with two anemia treatment options described in terms of five attributes (mode of administration, need for iron supplementation, risk of gastrointestinal [GI] side effects, risk of major CV events, and impact on energy levels). A multinomial logit model with an error component was used to analyze participants’ choices and estimate their treatment preferences. Estimated preferences were used to determine maximum level of CV and GI risk that patients were willing to tolerate to improve other treatment features.
Results
Between November 2019 and March 2020, 200 eligible patients (53% male) completed the DCE survey. The mean (SD) age was 53.78 (12.73) years; patients had been diagnosed with CKD 6.02 (7.49) years prior, and with CKD anemia 3.45 (3.44) years prior. Patients were found, on average, to value each of the five attributes associated with the treatments of CKD anemia. Patients were willing to tolerate a 5.12% (95% CI: 1.99; 8.25) increase in the risk of a major CV event and an 11.73% (95% CI: 4.96; 18.50) increase in the risk of GI side effects to switch from an at-home SC injection administered once every 2 weeks to an at-home oral pill administered three times a week. Patients would be willing to tolerate a 20.31% increase in the risk of GI side effects and an 8.86% increase in the risk of a major CV event to move from sometimes having a lot of energy to always having a lot of energy.
Conclusion
Patients would be willing to tolerate increased risks of CV and GI events to obtain an oral treatment for NDD CKD anemia and to always have a lot of energy.
Funding
- Commercial Support – Astellas Pharma, Inc.